PT  - JOURNAL ARTICLE
AU  - Zhang, Quan
AU  - Liu, Tiantian
AU  - Zhang, Linlin
AU  - Yang, Rongcheng
AU  - Zhao, Yao
AU  - Sun, Xiaojing
AU  - Wang, Ting
AU  - Kuang, Xiaoxiao
AU  - Liu, Hengfang
AU  - Liang, Jiao
AU  - Liu, Ya
AU  - Feng, Tao
TI  - Circulating Inflammatory Cytokines and Risk of Intracranial Aneurysm: A Mendelian-randomization Study
AID  - 10.1101/2023.12.17.23300093
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.12.17.23300093
4099  - http://medrxiv.org/content/early/2023/12/18/2023.12.17.23300093.short
4100  - http://medrxiv.org/content/early/2023/12/18/2023.12.17.23300093.full
AB  - Background Multiple studies have established the significant influence of inflammatory factors on the initiation and advancement of intracranial aneurysm (IA). However, the causality between specific inflammatory cytokines and IA remains uncertain. This study aims to elucidate it using Mendelian randomization (MR).Methods The genetic data of cytokines were collected from a genome-wide association study (GWAS) conducted on circulating cytokines in the Finnish population, involving the genetic characteristics of 41 cytokines obtained through a meta-analysis of 8,293 samples. The genetic data for IA were derived from the most extensive GWAS study, which included 7,495 samples from individuals of European ancestry and 71,934 healthy control subjects. The inverse variance weighted method primarily determined the causal correlation between exposures and outcomes. In addition, other robust MR analysis methods and sensitivity analyses were utilized to guarantee the accuracy of the results.Results Our results indicate a negative correlation between IP-10 and unruptured intracranial aneurysms (UIA) (odds ratio, OR: 0.63, 95%CI: 0.45-0.9, p=0.01). IL-10 and VEGF exhibit a positive correlation with aneurysmal subarachnoid hemorrhage (aSAH) (OR: 1.19, 95%CI: 1.02-1.39, p=0.024; OR: 1.12, 95%CI: 1.01-1.23, p=0.025). The levels of FGFBasic and TRAIL exhibit a negative correlation with aSAH. (OR: 0.62, 95%CI: 0.42-0.92, p=0.018; OR: 0.89, 95%CI: 0.8-1, p=0.041). The increased levels of IL-12p70, IL-4, IFNg, IL-10, IL-17, IL-1ra, IL-6, IL-9, VEGF, and FGFBasic were observed as the consequence of IA. (Beta: 0.18, 95%CI: 0.08-0.28, p=6.2e-4; Beta: 0.15, 95%CI: 0.07-0.23, p=2e-4; Beta: 0.15, 95%CI: 0.07-0.23, p=3.5e-4; Beta: 0.13, 95%CI: 0.05-0.21, p=1.4e-3; Beta: 0.1, 95%CI: 0.02-0.18, p=0.015; Beta: 0.17, 95%CI: 0.02-0.32, p=0.031; Beta: 0.14, 95%CI: 0.05-0.32, p=0.003; Beta: 0.13, 95%CI: 0.01-0.24, p=0.035; Beta: 0.14, 95%CI: 0.05-0.23, p=0.002; Beta: 0.09, 95%CI: 0.01-0.17, p=0.032).Conclusion Our study suggests that IP-10 may serve as a protective factor for UIA. FGFBasic and TRAIL have demonstrated a defensive impact against aSAH, while IL-10 and VEGF have been identified as factors that elevate the risk of IA rupture. Additionally, the levels of IL-12p70, IL-4, IFNg, and various cytokines are increased due to IA pathogenesis, and these cytokines may have the function of controlling inflammation in the progression of IA.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was financially supported by the National Natural Science Foundation of China (grant number no. 81901326).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study used (or will use) ONLY openly available human data that were originally located at:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5223028/, and https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7116530/.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.